The Research Institute of Biological Safety Problems of the Republic reported that QazCOVID-in is undergoing the third stage of clinical trials, which are planned to be fully completed in June
NUR-SULTAN, March 10. /TASS/. The Kazakh authorities plan to start mass production of a local vaccine against the QazCOVID-in coronavirus in April this year. This was reported to TASS on Wednesday at the Scientific Research Institute of Problems of Biological Safety of the republic, in which this drug was created.
“Mass production of the vaccine is scheduled to begin in April. The volume and place of production are currently determined by the authorized body of the Ministry of Health of Kazakhstan,” the response to the agency’s request says.
According to the agency, the vaccine is undergoing the third stage of clinical trials, which are planned to be fully completed in June this year. “In clinical trials, the vaccine has shown high safety and immunogenicity. When used correctly, it creates immunity in all vaccinated participants,” the Research Institute noted, speaking about the results of the first two stages of the QazCOVID-in trials.
As part of the third stage of vaccine research, 3 thousand volunteers were vaccinated in December 2020 and January of this year, who did not show any negative reactions afterward. “Clinical trials of the third phase of the vaccine and the selection of volunteers were carried out according to the protocol approved by the Ministry of Health. According to the accepted rules, the volunteers received a reward. After vaccination, no serious adverse events related to vaccination were detected among the participants,” was clarified the institute.
Inactivated vaccine
Scientists and specialists of the Research Institute of Biological Safety Problems worked on the creation of Kazakhstan’s inactivated QazCOVID-in vaccine. Their work is based on the experience of creating vaccines against other diseases, including highly pathogenic avian influenza and swine flu. Foreign specialists were not involved in the development of the vaccine.
“The domestic technology uses a virus isolated on the territory of Kazakhstan in inactivated form. Considering that the virus is whole and killed, the vaccine has a fairly high degree of immunogenicity and safety. In the Russian Sputnik V vaccine, a live adenovirus with a genetic site of the coronavirus infection virus is used as a carrier,” the Research Institute explained, answering the question about the difference between the Kazakh and Russian vaccines from the coronavirus.
On January 28, Prime Minister of Kazakhstan Askar Mamin instructed to ensure the release of a pilot batch of QazCOVID-in vaccine in the republic on the basis of the Research Institute of Biological Safety Problems and a pilot batch – at the production site of “SPE Antigen” LLP. The QazCOVID-in vaccine was included to the register of the World Health Organization.
On March 1, the Minister of Health of Kazakhstan Alexey Tsoi announced that his department plans to start vaccinations with a local coronavirus vaccine in April this year. Earlier, he said that according to preliminary data, the effectiveness of the drug was over 90%.
On February 1, Kazakhstan started vaccination of the population against coronavirus infection using the Sputnik V vaccine, which was produced in Russia. At the end of February, the shipment of the drug “Sputnik V” produced on the basis of the Karaganda pharmaceutical complex began to the regions of the country.
https://tass.ru/obschestvo/10866757